Abpro Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Trials    News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ABP-300 / Abpro Therap, BIO invest, Mabwell (Shanghai) Biosci
NCT04627584: A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19

Checkmark Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: A Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.
Checkmark Safety and immunogenicity data for COVID-19 treatment
Recruiting
2
150
RoW
MW33 injection, MW33 injection placebo
Mabwell (Shanghai) Bioscience Co., Ltd.
Covid19
05/21
09/21
ABP-160 / Abpro Therap
No trials found
ABP-500 / Abpro Therap
No trials found
ABP-201 / Abpro Therap, Abpro Bio
No trials found
ABP-110 / Abpro Therap
No trials found
ABP-150 / Abpro Therap
No trials found

Download Options